These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3939625)

  • 1. Altered responding to cholecystokinins and dopaminergic agonists following 6-hydroxydopamine treatment in rats.
    Hsiao S; Katsuura G; Itoh S
    Behav Neurosci; 1985 Oct; 99(5):853-60. PubMed ID: 3939625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G; Itoh S; Hsiao S
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
    Weiss F; Ettenberg A; Koob GF
    Psychopharmacology (Berl); 1989; 99(3):409-15. PubMed ID: 2574480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin tetrapeptide, proglumide and open-field behavior in rats.
    Hsiao S; Katsuura G; Itoh S
    Life Sci; 1984 May; 34(22):2165-8. PubMed ID: 6727557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral effects of cholecystokinin and its related peptides in rats.
    Itoh S; Katsuura G
    Prog Clin Biol Res; 1985; 192():139-45. PubMed ID: 2934743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats.
    Katsuura G; Itoh S
    Peptides; 1986; 7(5):809-14. PubMed ID: 3797342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking of cholecystokinin octapeptide behavioral effects by proglumide.
    Katsuura G; Hsiao S; Itoh S
    Peptides; 1984; 5(3):529-34. PubMed ID: 6089145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cholecystokinin tetra and octa peptides on locomotor activity in mice.
    Takeda Y; Takano Y; Kamiya H
    Jpn J Pharmacol; 1986 Sep; 42(1):145-9. PubMed ID: 3795615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cholecystokinin on apomorphine-induced changes of motility in rats.
    Katsuura G; Itoh S; Rehfeld JF
    Neuropharmacology; 1984 Jul; 23(7A):731-4. PubMed ID: 6089021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptide.
    Tanimoto K; Tamminga CA; Chase TN; Nilaver G
    Endocrinology; 1987 Jul; 121(1):127-32. PubMed ID: 3297634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of cholecystokinin octapeptide and food intake in male rats treated with cholecystokinin octapeptide.
    Lindén A; Uvnäs-Moberg K; Forsberg G; Bednar I; Södersten P
    J Endocrinol; 1989 Apr; 121(1):59-65. PubMed ID: 2565947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin and gastrin induce cell contraction in pig ileum by interacting with different receptor subtypes.
    Botella A; Delvaux M; Berry P; Frexinos J; Bueno L
    Gastroenterology; 1992 Mar; 102(3):779-86. PubMed ID: 1537515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sulfated cholecystokinin octapeptide and cholecystokinin tetrapeptide in rat behavior after blockade of nitric oxide synthase by L-NAME.
    Hoły Z; Wiśniewski K
    Rocz Akad Med Bialymst; 1998; 43():250-70. PubMed ID: 9972062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiological effects of cholecystokinin octapeptide on identified rat nigrostriatal dopaminergic neurons.
    Freeman AS; Chiodo LA
    Brain Res; 1988 Jan; 439(1-2):266-74. PubMed ID: 3359189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of A9 and A10 dopaminergic neurons in unrestrained rats: further characterization and effects of apomorphine and cholecystokinin.
    Freeman AS; Bunney BS
    Brain Res; 1987 Mar; 405(1):46-55. PubMed ID: 3032350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of acetylcholine release by cholecystokinin in striatum: receptor specificity; role of dopaminergic neuronal activity.
    Petkova-Kirova P; Giovannini MG; Kalfin R; Rakovska A
    Brain Res Bull; 2012 Dec; 89(5-6):177-84. PubMed ID: 22981453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion.
    Crawley JN
    Synapse; 1989; 3(4):346-55. PubMed ID: 2740993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain.
    Costall B; Marsden CD; Naylor RJ; Pycock CJ
    Brain Res; 1976 Dec; 118(1):87-113. PubMed ID: 990957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A behavioural pharmacological study on intracerebroventricularly administered CCK-8 related peptides in mice.
    Hagino Y; Moroji T; Iizuka R
    Neuropeptides; 1989; 13(2):107-13. PubMed ID: 2739882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat.
    Marek GJ; Vosmer G; Seiden LS
    Brain Res; 1990 May; 516(1):1-7. PubMed ID: 2142010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.